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Objectives: To compare cognitive and emotional outcomes 
between patients with aneurysmal and perimesencephalic 
subarachnoid haemorrhage and norm scores.
Design: First measurement in prospective cohort study.
Patients: Sixty-seven patients with subarachnoid haemorr-
hage, were divided into perimesencephalic (n = 8) and aneu-
rysmal (n = 59) subarachnoid haemorrhage groups.
Methods: Patients completed several questionnaires within 
the first year after haemorrhage. Depression was measured 
with the Center for Epidemiologic Studies Depression scale, 
fatigue with the Fatigue Severity Scale, and objective cogni-
tive functioning with the Trail Making Test. Glasgow Coma 
Scale scores were collected at hospital admission.
Results: Perimesencephalic patients had lower depression 
(p = 0.006) and lower fatigue scores (p = 0.029) and were faster 
on the Trail Making Test A (p = 0.002) than aneurysmal pa-
tients. No differences between the groups were found on Trail 
Making Test B (p = 0.112) and presence of fatigue (p = 0.105). 
Compared with norm scores, aneurysmal patients scored sig-
nificantly worse on all outcomes, whereas perimesencephalic 
patients scored worse on Trail Making Test B (p < 0.008), fa-
tigue (p = 0.073) and presence of fatigue (p = 0.058).
Conclusion: Perimesencephalic patients may experience pro-
blems in complex cognitive functioning and fatigue. In this 
respect, they have similar sequelae as aneurysmal patients, 
which may interfere with daily activities and social participa-
tion. These findings are of clinical relevance, as perimesen-
cephalic patients often are discharged from hospital without 
long-term follow-up.
Key words: perimesencephalic subarachnoid haemorrhage; an-
eurysmal subarachnoid haemorrhage; cognition; fatigue.
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INTRODUCTION
Subarachnoid haemorrhage (SAH) is a subtype of stroke that 
occurs at a relatively young age. The mean age of onset of 
SAH is 55 years (1), compared with 70 years in men and 75 
years in women for stroke in general (2). The overall case 
fatality rate is 50% in population-based studies. Only 5% of 
all strokes are SAH, with an incidence in the Netherlands of 
5.8 per 100,000 persons per year for men and 9.9 for women 
(3, 4). In approximately 15% of all SAHs, no structural cause 
for the haemorrhage can be identified on radiographic imag-
ing, termed angiogram-negative SAH, previously described 
as SAH of unknown origin or non-aneurysmal SAH (5–8). 
This group can be subdivided into perimesencephalic and 
non-perimesencephalic angiogram-negative SAH (9–13). This 
study focuses on 2 subtypes of SAH based on the cause of the 
haemorrhage: aneurysmal subarachnoid haemorrhage (A-SAH) 
and perimesencephalic subarachnoid haemorrhage (PM-SAH) 
(3). PM-SAH is defined as a haemorrhage restricted to the 
cisterns surrounding the brainstem and the suprasellar cistern 
combined with a negative angiogram (3, 7, 14). The cause of 
PM-SAH is unknown and no surgical treatment is required (3).
A-SAH covers 85% of all SAH and is characterized by 
the rupture of an intracranial aneurysm and the subsequent 
accumulation of blood in the subarachnoid space (3, 15). 
Neuroradiological intervention or neurosurgical clipping are 
the 2 options for treatment of the ruptured aneurysm (3, 15). 
PM-SAH accounts for 10% of all SAH cases and the remaining 
5% has various other causes (3, 7). In 1985 van Gijn et al. (16) 
first described PM-SAH as a benign form of SAH. 
Several studies have suggested that patients with A-SAH 
have a significantly less favourable prognosis than patients 
with PM-SAH, based on the need for surgical or endovascu-
lar treatment, risk of re-bleeding, shorter life expectancy and 
reduced quality of life (1, 5, 15, 17–22). Of the patients who 
survive, approximately one-third remain dependent (Rankin 
grade 3–5) (23). Even those who are independent may have 
cognitive impairments after recovery from A-SAH, in par-
ticular in the domains memory, executive functioning and 
language. Furthermore, half of the A-SAH patients experience 
mood disturbances and one-third experience fatigue (15, 21, 
22, 24). Therefore, the majority of patients with A-SAH are 
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referred to inpatient or outpatient rehabilitation services or 
nursing homes for follow-up treatment (25, 26).
Patients with PM-SAH have a shorter length of stay in 
hospital, and are considered to experience good recovery not 
requiring follow-up treatment or meeting the criteria for re-
habilitation services (27). Most studies showing these results 
are focused on survival and clinical outcomes (10, 12, 13, 28, 
29). However, the premise of good functional outcome and 
cognitive functioning of PM-SAH is unclear. Only 2 studies 
were found confined to cognition and psychosocial outcome 
in the subgroup of PM-SAH patients (18, 30). In these stud-
ies several problems are reported, such as cognitive deficits, 
depression, reduced activity levels, headaches, irritability and 
psychosocial problems, such as returning to a (current) job (18, 
30, 31). However, in a long-term follow-up study in angiogram-
negative SAH patients, problems in selective attention during 
the first year of follow-up were found, which normalized within 
3 years (9). Two studies comparing the diverse group of SAH 
patients of unknown origin with selected A-SAH patients, 
reported impairments in diffuse cognitive functions, such as 
attention in the first group vs focal cognitive functions, such 
as short- and long-term memory, in the latter group (6, 8). 
Outcome studies comparing isolated PM-SAH and A-SAH 
are not available, to our knowledge.
The aim of this study was to investigate the differences in 
cognitive and emotional outcomes of the subgroup PM-SAH 
and A-SAH patients in the first year after SAH. Based on the 
literature, we expect that patients with PM-SAH will have 
better outcomes than those with A-SAH, but we also expect 
to find cognitive problems and mood disturbances in patients 
with PM-SAH that might require medical attention or follow-
up treatment in rehabilitation services.
METHODS
Participants and procedures
All patients diagnosed with SAH, who were hospitalized between 2006 
and 2009 at the neurology or neurosurgery department of the Erasmus 
University Medical Centre Rotterdam, were screened for participa-
tion in this study. Inclusion criteria were: at least 18 years of age and 
survival of SAH at least until hospital discharge. Exclusion criteria 
were: serious co-morbidity resulting in a short life expectancy less than 
1 year and insufficient mastering of the Dutch language. Patients who 
agreed to participate were asked to sign an informed consent form. The 
study was approved by the medical ethics committee of Erasmus MC.
Data collection
The presence of SAH was determined by computed tomography (CT) 
or lumbar puncture. The cause of SAH was determined using CT angio-
graphy or digital subtraction angiography. PM-SAH was defined by 
accumulation of blood around the mesencephalon on CT and a normal 
4-vessel angiogram (3, 14). 
During hospitalization baseline socio-demographic data and clinical 
characteristics, such as type, location and severity of SAH, and type of 
rehabilitation (none, outpatient, or inpatient rehabilitation) were col-
lected by the staff of the neurology or neurosurgery department. within 
the first year after SAH a research psychologist visited the patients at 
home to collect different measurements, which included validated ques-
tionnaires for depression and fatigue, and an objective test for cognitive 
functioning. Data were collected by 3 trained research psychologists.
Normative data from healthy subjects were obtained from the litera-
ture for each of the questionnaires and for the cognitive functioning 
test (32–34).
Measurement instruments
The barthel Index (bI) is used to evaluate the patient’s state of inde-
pendence. The total score ranges from 0 to 20, where 0 is completely 
dependent and 20 is completely independent (35).
Glasgow Coma Scale scores (GCS) were collected as a measure of 
the severity of the SAH. The GCS is a scale to measure 3 different 
aspects of impaired consciousness and coma: motor response, verbal 
response and eye opening. The total score ranges from 3 to 15, of 
which the higher scores represent a higher level of consciousness (36). 
In this study the first GCS score during hospital admission was used. 
These scores were assessed by physicians of the hospital department. 
The Center for Epidemiological Studies Depression scale (CES-D) 
was used to measure emotional outcome. CES-D is a 20-item scale used 
to measure depressive symptoms over the previous week in a general 
population. This scale is validated in stroke patients (37). Scores range 
from 0 to 60 and the higher the score, the more depressive symptoms 
are present. Scores of 16 or higher are an indication of presence of 
depression (32, 37, 38). 
The Fatigue Severity Scale (FSS) was used to measure the severity 
of fatigue. The questionnaire has 9 statements on fatigue in daily life. 
The patient can score these statements on a 7-point likert scale, ranging 
from 1 to 7, where 1 is “strongly disagree” and 7 is “strongly agree”. 
based on the literature, patients with fatigue are distinguished from 
healthy controls if the mean score of the 9 items is 4 or higher (33). 
The Trail Making Test (TMT), parts A and b, were used as a 
measure of cognitive functioning. The TMT is widely used and has 
been researched extensively. The TMT score is a neuropsychological 
measure that is sensitive to a wide range of neurocognitive deficits 
(39). The TMT is a pen and paper task to measure cognitive flexibility. 
In part A, which measures motor speed and processing speed, patients 
are asked to connect 25 numbered dots in ascending order as quickly 
as possible. In part b, which measures processing speed and divided 
attention, the 25 dots contain numbers and letters and the patient 
must connect the dots alternating between a number and a letter. The 
measured time (with a maximum of 180 s), including extra time for 
correcting potential errors, is recorded to calculate a time score (40).
Statistical analysis
Statistical analyses were performed using SPSS version 19 (SPSS Inc, 
Chicago, Il, USA). Descriptive statistics were used to describe the gen-
eral population characteristics. Means and standard deviations (SDs) 
were calculated for interval variables and numbers and percentages 
for categorical variables. Mann-whitney U tests were used to analyse 
the differences between patients with PM-SAH and those with A-SAH 
for the variables: GCS, CES-D and FSS and independent-samples t-
test for the TMT A and b scores. Fisher’s exact tests were used to test 
the differences between the SAH types of the categorical variables: 
gender, education (≥ high school), hypertension, smoking presence of 
depression (CES-D > 16) and presence of fatigue (FSS > 4). Type of 
rehabilitation (inpatient/outpatient/none) was tested with the χ2 test. 
Fig. 1. Patient inclusion. SAH: subarachnoid haemorrhage.
 
 
 
Total SAH (n=228) 
- Died (n=63) 
- Excluded (n=30) 
- Missed (n=19) 
!
Analysed (n=67)  
- Declined (n=20) 
- Missed (n=29) 
Eligible (n=116)
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To test for potential selection bias, differences between the groups 
of missed patients and included patients (see Fig. 1) were evaluated. 
For all analyses a significance level of p < 0.05 was used.
Comparisons of the PM-SAH and A-SAH group with norm values 
of healthy subjects were performed with independent-samples t-test 
and Fisher’s exact tests, using a statistical internet tool (GraphPad 
Software Inc, la Jolla, CA, USA).
RESUlTS
Study population
From a total of 228 patients with SAH, who were hospitalized 
in the neurology or neurosurgery department of the Erasmus 
MC between April 2006 and August 2009, 67 were eligible for 
inclusion in the study. The flow of patients is shown in Fig. 1. 
Eight of the included patients had a PM-SAH (11.9%) and 59 had 
an A-SAH (88.1%). None of the patients in this sample was di-
agnosed with non-perimesencephalic angiogram-negative SAH. 
The mean age of the study population was 53.1 years (SD 11.6) 
and 37.3% were male. The mean length of hospital stay was 15.3 
days (SD 9.9). Patient characteristics are presented in Table I.
No significant differences were found between the groups of 
missed patients and included patients for any of the variables 
available: type of bleeding, gender, age, length of stay and 
Glasgow Coma Scale scores (Table I). Data were complete for 
92.5% of the TMT-A, 89.6% of the TMT-b, 83.6% of the FSS 
and 77.6% of the CES-D. The main reason for the missing data 
was the length of the test battery: time restrictions or fatigue 
were reasons for not finishing the test battery. Sum scores could 
sometimes not be calculated because of missing item scores. 
Comparison between PM­SAH and A­SAH patients
Compared with the A-SAH group, the PM-SAH group con-
tained significantly more men and had a shorter length of stay 
(Table II). bI score, age and other patient characteristics did 
not differ significantly between the 2 groups. Rehabilitation 
type was also not significant. One PM-SAH patient received 
outpatient rehabilitation for cognitive complaints only. From 
the A-SAH patients 27.1% received inpatient rehabilitation 
including multidisciplinary functional and cognitive therapy. 
Table III presents the results of the questionnaires and cogni-
Table I. Patient characteristics
 
Analysed 
group 
(n = 67)
Missed 
group 
(n = 29) p-values
Age, years, mean (SD) 53.1 (11.6) 56.4 (12.0) 0.207a
length of hospital stay, days, mean 
(SD) 15.3 (9.9) 16.3 (9.0) 0.645a
GCS, mean (SD) 13.2 (3.4) 12.2 (4.0) 0.425b
Time after SAH, months, mean 
(SD) 5.6 (8.6) NA NA
Type of bleeding, 
perimesencephalic, n (%) 8 (11.9) 3 (10.3) 1.000c
Gender, men, n (%) 25 (37.3) 11 (37.9) 1.000c
Education, ≥ high school, n (%) 32 (47.8) NA NA
Hypertension, n (%) 29 (43.9) NA NA
Smoking, n (%) 27 (40.9) NA NA
at-test; bMann-whitney U test; cFisher’s exact test.
SAH: subarachnoid haemorrhage; GCS: Glasgow Coma Scale score; 
SD: standard deviation; NA: not available.
Table II. Comparison of patient characteristics between perimes­
encephalic subarachnoid haemorrhage (PM­SAH) and aneurysmal 
subarachnoid haemorrhage (A­SAH) patients
 
PM-SAH 
(n = 8)
A-SAH
(n = 59)
PM-SAH
vs A-SAH
p-values
Age, years, mean (SD) 48.9 (10.4) 53.6 (11.7) 0.278a
Time after SAH, months,  
mean (SD) 3.2 (2.5) 6.0 (9.1) 0.390a
length of hospital stay, days, 
mean (SD) 7.1 (6.6) 16.4 (9.8) 0.012a
GCS, mean (SD) 14.8 (0.5) 13.0 (3.5) 0.121b
bI, mean (SD) 19.9 (0.4) 18.6 (2.9) 0.051b
Gender, men, n (%) 6 (75.0) 19 (32.2) 0.045c
Type of rehabilitation, n (%)
Inpatient 
Outpatient 
None 
0 (0.0)
1 (12.5)
7 (87.5)
16 (27.1)
7 (11.9)
36 (61.0)
0.230d
Education, ≥ high school, n (%) 5 (62.5) 27 (45.8) 0.464c
Hypertensiond, n (%) 3 (37.5) 26 (44.8) 1.000c
Smokingd, n (%) 2 (25.0) 25 (43.1) 0.455c
at-test; bMann-whitney U test; cFisher’s exact test; dχ2 test.
SAH: subarachnoid haemorrhage; GCS: Glasgow Coma Scale score; 
bI: barthel Index score.
Table III. Comparisons of outcomes between perimesencephalic subarachnoid haemorrhage (PM­SAH), aneurysmal subarachnoid haemorrhage 
(A­SAH) patients, and norm values
Measurement PM-SAH n A-SAH n Norm values n
PM-SAH
vs A-SAH
p-values
PM-SAH
vs norm
p-values
A-SAH
vs norm
p-values
CES-D, mean (SD) 5.0 (4.9) 7 13.9 (8.7) 45 8.2 (7.2) 255 0.006b 0.244a 0.000a
CES-D ≥ 16, n (%) 0 (0.0) 7 20 (44.4) 45 32 (12.7) 255 0.035c 0.601c 0.000c
FSS, mean (SD) 3.1 (1.6) 8 4.5 (1.4) 48 2.3 (0.7) 20 0.029b 0.073a 0.000a
FSS ≥ 4, n (%) 3 (37.5) 8 34 (70.8) 48 1 (5.0) 20 0.105c 0.058c 0.000c
TMT-A, mean (SD) 33.0 (8.3) 7 47.9 (20.1) 56 31.8 (9.9) 41 0.002a 0.764a 0.000a
TMT-b, mean (SD) 87.0 (42.4) 7 118.8 (49.1) 56 63.8 (14) 41 0.112a 0.008a 0.000a
at-test; bMann-whitney U test; cFisher’s exact test.
CES-D: Center for Epidemiologic Studies-Depression Scale score; FSS: Fatigue Severity Scale score; TMT-A and TMT-b: Trail Making Test A and 
b scores; SD: standard deviation.
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tive testing. The PM-SAH patients had lower depression scores 
and fatigue scores compared with A-SAH patients. None of the 
PM-SAH patients had a significant depression (CES-D ≥ 16) 
vs 20 (44.4%) in the A-SAH group. However, the proportion 
of PM-SAH patients with fatigue (FSS score ≥ 4) was not 
significantly different from the A-SAH patients. For the tasks 
of cognitive functioning significant differences were found at 
the TMT-A. Patients with PM-SAH were faster on this task 
than those with A-SAH. No significant differences were found 
between the 2 groups on the more complex TMT-b task. 
Comparison of PM­SAH vs norm values
Comparing the results with the scores of a normal healthy popu-
lation we found that patients with A-SAH scored significantly 
worse on all outcome measures. Patients with PM-SAH scored 
significantly worse than the norm population on the more 
complex TMT-b task (Table III). In addition, the mean fatigue 
scores of the patients with PM-SAH and the proportion of 
these patients with a FSS score ≥ 4 were borderline significant 
compared with the healthy subjects. No significant differences 
were found for the depression scores and the TMT-A task. 
DISCUSSION
Our results show disturbed cognitive and emotional outcomes 
in patients with PM-SAH, also found in other studies (18, 30, 
31). The cognitive task, TMT-A, indicates that patients with 
PM-SAH have no problems in processing and motor speed, 
in contrast with patients with A-SAH, which is in agreement 
with our hypothesis. However, the results on the more complex 
TMT-b task indicate that both groups of SAH patients perform 
worse than a normative sample. This implies that divided atten-
tion is affected in both the PM-SAH and A-SAH patients. This 
confirms the findings of Madureira et al. (18), in which 72% of 
the patients with PM-SAH showed neuropsychological deficits, 
and Hütter et al. (6), who found similar cognitive deficits in 
non-A-SAH patients in comparison with A-SAH patients. 
Another notable finding in our study is that the proportion of 
patients with PM-SAH with fatigue did not differ significantly 
from that of patients with A-SAH, and it almost significantly dif-
fered from the normative scores. To our knowledge, fatigue was 
not investigated in other studies with validated questionnaires in 
patients with PM-SAH. This finding suggests that patients with 
PM-SAH, like those with A-SAH, do experience fatigue, which 
is described as a common complaint after SAH (24).
Contrary to our expectations, none of the patients with PM-
SAH in our study reached the CES-D cut-off score of 16, which 
indicates clinical depression. This finding differs from earlier 
literature in which, besides the cognitive deficits symptoms of 
depression in PM-SAH patients are also reported (9, 18, 30). 
A possible explanation is that, in our study, the majority of pa-
tients with PM-SAH was male. Gender is a known predictor for 
symptoms of depression, and could therefore have influenced 
the outcome of the CES-D (32). In the study of Madureira et 
al. (18), for example, 66% of the patients with PM-SAH with 
depression were female. Of the patients with A-SAH in our 
study, 44.4% had clinical depression (1, 15). The difference 
between A-SAH and PM-SAH might be explained by the dif-
ferent prospects of both groups. Patients with PM-SAH do not 
require surgical or radiological treatment and get an excellent 
clinical prognosis without the risk of a re-bleed and without 
follow-up treatment, whereas A-SAH patients are faced with 
complex treatment, high complication rates, a survival chance 
of only 50%, a high risk of recurrence and many of them face 
months of rehabilitation (1, 15). 
Although the results of this study of impaired complex cogni-
tive functioning and fatigue in patients with PM-SAH confirm 
previous research findings, not much has changed in terms of 
follow-up treatment for patients with PM-SAH in the Nether-
lands. Patients with PM-SAH often are discharged from hospital 
without long-term follow-up because of their good prognosis. 
based on our results, this policy should be questioned. 
This study has some limitations. The first is that there were 
only 8 PM-SAH and 59 A-SAH patients enrolled in the study. 
Even with this small number of PM-SAH patients we did find 
significant cognitive deficits compared with a normal popula-
tion. In terms of percentage, this number fits the incidence of 
10% of all SAH patients. In further research a larger sample is 
required to confirm that PM-SAH patients experience fatigue. 
Another limitation might be that the measurement time, within 
the first year after the haemorrhage, was not the same for all 
patients, and no follow-up measurements were done. In recent 
research it was found that cognitive complaints may dimin-
ish within 3 years of follow-up (9). Finally, cognitive testing 
was limited to the TMT test, which is a good test to measure 
processing speed and mental flexibility. In future studies other 
domains of cognitive functioning, such as long-term memory 
and sustained attention, should be measured in a larger sample 
over a longer follow-up.
In conclusion, contrary to the assumed favourable outcome, 
patients with PM-SAH may experience impaired complex cog-
nitive functioning and fatigue. In this respect patients with PM-
SAH have similar sequelae to those with A-SAH, which may 
interfere with daily activities and social participation. These 
findings are of clinical relevance, as patients with PM-SAH 
often are discharged from hospital without long-term follow-
up. based on our results this policy should be questioned. 
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